Q-omics provides the consensus-scored RN7SL569P profile across patient tissues and cancer cell-line models. RN7SL569P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RN7SL569P is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, RN7SL569P RNA expression shows 13,228 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where RN7SL569P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL569P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL569P survival associations across molecular data types. RN7SL569P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL569P RNA expression–survival associations across cancer types. High RN7SL569P expression shows unfavorable associations in KIRC, THCA, MESO and COAD, but favorable associations in SKCM and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RN7SL569P RNA expression.
This table summarizes RN7SL569P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL569P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL569P shows higher tumor expression in HNSC, LUSC, BRCA, LUAD, STAD and COAD. The HNSC box plot shows higher RN7SL569P RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .005).
This table shows molecular features associated with RN7SL569P in patient tissues and cancer cell lines. In patient samples, RN7SL569P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
